Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Indian Science
  4. Volume 2, Issue 1
  5. Article
Volume 2, Issue 1
  • ISSN: 2210-299X
  • E-ISSN: 2210-3007
file format pdf download PDF
side by side viewer icon HTML

Abstract

Diabetes Mellitus (DM) is a metabolic syndrome that gradually leads to chronic microvascular or macrovascular complications. There are 2 types of DM: Insulin-dependent diabetes, commonly called type I DM, is an organ-specific autoimmune disorder that destroys the body’s pancreatic β cells, causing insulin deficiency, and can be treated through insulin replacement therapy. Non-insulin-dependent diabetes mellitus, or type II DM, is caused by pancreatic cell dysfunction that affects a person’s ability to use insulin and can be treated with oral hypoglycaemics. Recent investigation confirms that combination therapy of metformin (biguanides), sodium-glucose co-transporter-2 (SGLT2) inhibitors, and Dipeptidyl Peptidase-4 (DPP-4) inhibitors not only reduces HbA1c glucose dependently but also provides better sustained glycaemic stability with good tolerability in comparison to monotherapy. Multi-particulate drug delivery provides targeted drug administration with high bioavailability and compressed dosage administration. In this review analysis, an effort has been made to explore the pathophysiology of type II DM and the importance of combination therapy using microspheres for the delivery of drugs for the management of type II DM.

© 2024 The Author(s). Published by Bentham Science Publisher.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/cis/10.2174/012210299X306155240926065025
2024-11-20
2025-03-01

  • From This Site

    /content/journals/cis/10.2174/012210299X306155240926065025
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
The full text of this item is not currently available.

References

  1. KhanM.A.B. HashimM.J. KingJ.K. GovenderR.D. MustafaH. Al KaabiJ. Epidemiology of type 2 diabetes: Global burden of disease and forecasted trends.J. Epidemiol. Glob. Health201910110711110.2991/jegh.k.191028.00132175717
     [Google Scholar]
  2. PradeepaR. MohanV. Epidemiology of type 2 diabetes in India.Indian J. Ophthalmol.202169112932293810.4103/ijo.IJO_1627_2134708726
     [Google Scholar]
  3. SaeediP. PetersohnI. SalpeaP. MalandaB. KarurangaS. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition.Diabetes Res Clin Pract201915710784310.1016/j.diabres.2019.107843
     [Google Scholar]
  4. American Diabetes AssociationDiagnosis and classification of diabetes.Diabetes Care2010371S81S9010.2337/dc14‑S081
     [Google Scholar]
  5. PadhiS. NayakA.K. BeheraA. Type II diabetes mellitus: A review on recent drug based therapeutics.Biomed. Pharmacother.202013111070810.1016/j.biopha.2020.11070832927252
     [Google Scholar]
  6. Treatment of type IIDM in the older patient - UpToDate.2020
     [Google Scholar]
  7. TanS.Y. Mei WongJ.L. SimY.J. WongS.S. Mohamed ElhassanS.A. TanS.H. Ling LimG.P. Rong TayN.W. AnnanN.C. BhattamisraS.K. CandasamyM. Type 1 and 2 diabetes mellitus: A review on current treatment approach and gene therapy as potential intervention.Diabetes Metab. Syndr.201913136437210.1016/j.dsx.2018.10.00830641727
     [Google Scholar]
  8. NathanD.M. BuseJ.B. DavidsonM.B. FerranniniE. HolmanR.R. SherwinR. ZinmanB. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy.Diabetes Care200932119320310.2337/dc08‑902518945920
     [Google Scholar]
  9. DeyN.S. MajumdarS. RaoM.E.B. Multiparticulate drug delivery systems for controlled release.Trop. J. Pharm. Res.2008731067107510.4314/tjpr.v7i3.14692
     [Google Scholar]
  10. RöderP.V. WuB. LiuY. HanW. Pancreatic regulation of glucose homeostasis.Exp. Mol. Med.2016483e21910.1038/emm.2016.626964835
     [Google Scholar]
  11. RadziukJ. Homeostastic model assessment and insulin sensitivity/resistance.Diabetes20146361850410.2337/db14‑0116
     [Google Scholar]
  12. WilcoxG. Insulin and insulin resistance.Clin Biochem Rev2005262193916278749
     [Google Scholar]
  13. RahmanM.S. HossainK.S. DasS. KunduS. AdegokeE.O. RahmanM.A. HannanM.A. UddinM.J. PangM.G. Role of insulin in health and disease: An update.Int. J. Mol. Sci.20212212640310.3390/ijms2212640334203830
     [Google Scholar]
  14. HieshimaK. SugiyamaS. YoshidaA. KurinamiN. SuzukiT. IjimaH. MiyamotoF. KajiwaraK. JinnouchiK. JinnouchiT. JinnouchiH. Elevation of the renal threshold for glucose is associated with insulin resistance and higher glycated hemoglobin levels.J. Diabetes Investig.202011361762510.1111/jdi.1319131770476
     [Google Scholar]
  15. HabeggerK.M. HeppnerK.M. GearyN. BartnessT.J. DiMarchiR. TschöpM.H. The metabolic actions of glucagon revisited.Nat. Rev. Endocrinol.201061268969710.1038/nrendo.2010.18720957001
     [Google Scholar]
  16. OjhaA. OjhaU. MohammedR. ChandrashekarA. OjhaH. Current perspective on the role of insulin and glucagon in the pathogenesis and treatment of type 2 diabetes mellitus.Clin. Pharmacol.201911576510.2147/CPAA.S20261431191043
     [Google Scholar]
  17. QaidM.M. AbdelrahmanM.M. Role of insulin and other related hormones in energy metabolism: A review.Cogent Food Agric.20162111810.1080/23311932.2016.1267691
     [Google Scholar]
  18. NavaleA.M. ParanjapeA.N. Glucose transporters: Physiological and pathological roles.Biophys. Rev.2016815910.1007/s12551‑015‑0186‑228510148
     [Google Scholar]
  19. Galicia-GarciaU. Benito-VicenteA. JebariS. Larrea-SebalA. SiddiqiH. UribeK.B. OstolazaH. MartínC. Pathophysiology of type II DM.Int. J. Mol. Sci.20202117627510.3390/ijms21176275
     [Google Scholar]
  20. DeFronzoR.A. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus.Diabetes200958477379510.2337/db09‑902819336687
     [Google Scholar]
  21. Todd CadeW. Diabetes-related microvascular and macrovascular diseases in the physical therapy setting.Phys Ther2008881113223510.2522/ptj.20080008
     [Google Scholar]
  22. AminN. DoupisJ. Diabetic foot disease: From the evaluation of the “foot at risk” to the novel diabetic ulcer treatment modalities.World J. Diabetes20167715316410.4239/wjd.v7.i7.15327076876
     [Google Scholar]
  23. ChaudhuryA. DuvoorC. Reddy DendiV.S. KraletiS. ChadaA. RavillaR. MarcoA. ShekhawatN.S. MontalesM.T. KuriakoseK. SasapuA. BeebeA. PatilN. MushamC.K. LohaniG.P. MirzaW. Clinical review of antidiabetic drugs: Implications for type 2 diabetes mellitus management.Front. Endocrinol. (Lausanne)20178611210.3389/fendo.2017.00006
     [Google Scholar]
  24. AzimovaK. San JuanZ. MukherjeeD. Cardiovascular safety profile of currently available diabetic drugs.Ochsner J.201414461663225598727
     [Google Scholar]
  25. TsangMW. The management of type 2 diabetic patients with hypoglycaemic agents.ISRN Endocrinol2012201247812010.5402/2012/478120
     [Google Scholar]
  26. LipscombeL. ButaliaS. DasguptaK. EurichD.T. MacCallumL. ShahB.R. SimpsonS. SeniorP.A. Pharmacologic glycemic management of type 2 diabetes in Adults: 2020 update.Can. J. Diabetes202044757559110.1016/j.jcjd.2020.08.00132972640
     [Google Scholar]
  27. MishraG.P. SharmaR. JainM. BandyopadhyayD. Syntheses, biological evaluation of some novel substituted benzoic acid derivatives bearing hydrazone as linker.Res. Chem. Intermed.202147125061507810.1007/s11164‑021‑04555‑y
     [Google Scholar]
  28. HansenKB. VilsbøllT. KnopFK. Incretin mimetics: A novel therapeutic option for patients with type 2 diabetes - A review.Diabetes Metab. Syndr. Obes.2010173155163
     [Google Scholar]
  29. ChawlaR. ChawlaA. JaggiS. Microvasular and macrovascular complications in diabetes mellitus: Distinct or continuum?Indian J. Endocrinol. Metab.201620454655110.4103/2230‑8210.18348027366724
     [Google Scholar]
  30. Bin RakhisSA. AlDuwayhisNM. AleidN. AlBarrakAN. AlorainiAA. Glycemic control for type 2 diabetes mellitus patients: A systematic review.Cureus20221461810.7759/cureus.26180
     [Google Scholar]
  31. GalavizK.I. NarayanK.M.V. LobeloF. WeberM.B. Lifestyle and the prevention of type 2 diabetes: A status report.Am. J. Lifestyle Med.201812142010.1177/155982761561915930202378
     [Google Scholar]
  32. TusoP. Prediabetes and lifestyle modification: Time to prevent a preventable disease.Perm. J.2014183889310.7812/TPP/14‑00225102521
     [Google Scholar]
  33. JenaB.N. KalraS. YeravdekarR. Emotional and psychological needs of people with diabetes.Indian J. Endocrinol. Metab.201822569670410.4103/ijem.IJEM_579_1730294583
     [Google Scholar]
  34. García-PérezLE. AlvarezM. DillaT. Gil-GuillénV. Orozco-BeltránD. Adherence to therapies in patients with type 2 diabetes.Diabetes Ther20134217519410.1007/s13300‑013‑0034‑y23990497
     [Google Scholar]
  35. LeeY-C. ChangC-H. DongY-H. LinJ-W. WuL-C. HwangJ-S. ChuangL-M. Comparing the risks of hospitalized heart failure associated with glinide, sulfonylurea, and acarbose use in type 2 diabetes: A nationwide study.Int. J. Cardiol.20172282281007101410.1016/j.ijcard.2016.11.022
     [Google Scholar]
  36. LamosE.M. SteinS.A. DavisS.N. Combination of glibenclamide–metformin HCl for the treatment of type 2 diabetes mellitus.Expert Opin. Pharmacother.201213172545255410.1517/14656566.2012.73819623116560
     [Google Scholar]
  37. HermanW.H. BuseJ.B. ArakakiR.F. DunganK.M. JiangH.H. JacobsonJ.G. FahrbachJ.L. Concomitant oral antihyperglycemic agent use and associated treatment outcomes after initiation of insulin therapy.Endocr. Pract.201117456356710.4158/EP10348.OR21550959
     [Google Scholar]
  38. ChangT. LinH. LinF. Comparative outcomes of basal insulin and oral anti-diabetic agent as an add-on to dual therapy in patients with type 2 diabetes mellitus.Value Health201821S3610.1016/j.jval.2018.07.274
     [Google Scholar]
  39. WahlqvistM.L. LeeM-S. HsuC-C. ChuangS-Y. LeeJ-T. TsaiH-N. Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson’s disease occurring with Type 2 diabetes in a Taiwanese population cohort.Parkinsonism Relat. Disord.201218675375810.1016/j.parkreldis.2012.03.010
     [Google Scholar]
  40. DasR. LangermanH. D’OcaK. StrongmanH. An observational cohort study of diabetes-associated secondary health care utilisation in patients with type 2 diabetes prescribed dual combination therapy with oral anti-hyperglycaemic agents in the UK.Value Health2014177A36010.1016/j.jval.2014.08.78227200730
     [Google Scholar]
  41. KoufakisT. MustafaO.G. ZebekakisP. KotsaK. Oral antidiabetes agents for the management of inpatient hyperglycaemia: So far, yet so close.Diabet. Med.20203791418142610.1111/dme.1432932445407
     [Google Scholar]
  42. VijayakumarT.M. JayramJ. Meghana CheekireddyV. HimajaD. Dharma TejaY. NarayanasamyD. Safety, efficacy, and bioavailability of fixed-dose combinations in type 2 diabetes mellitus: A systematic updated review.Curr. Ther. Res. Clin. Exp.201784844910.1016/j.curtheres.2017.01.00528761573
     [Google Scholar]
  43. StaffordJ.M. ElasyT. Treatment update: Thiazolidinediones in combination with metformin for the treatment of type 2 diabetes.Vasc. Health Risk Manag.20073450351017969380
     [Google Scholar]
  44. KennethR. FeingoldM.D. Oral and injectable (non-insulin) pharmacological agents for the treatment of type 2 diabetes.Endotext2024
     [Google Scholar]
  45. AhrénB. Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.Vasc. Health Risk Manag.20084238339410.2147/VHRM.S194418561513
     [Google Scholar]
  46. MilderT.Y. StockerS.L. Abdel ShaheedC. McGrath-CadellL. Samocha-BonetD. GreenfieldJ.R. DayR.O. Combination therapy with an SGLT2 inhibitor as initial treatment for type 2 diabetes: A systematic review and meta-analysis.J. Clin. Med.2019814510.3390/jcm8010045
     [Google Scholar]
  47. MinS.H. YoonJ.H. HahnS. ChoY.M. Efficacy and safety of combination therapy with an α‐glucosidase inhibitor and a dipeptidyl peptidase‐4 inhibitor in patients with type 2 diabetes mellitus: A systematic review with meta‐analysis.J. Diabetes Investig.20189489390210.1111/jdi.1275428950431
     [Google Scholar]
  48. SeinoY. FukushimaM. YabeD. GIP and GLP-1, the two incretin hormones: Similarities and differences.J Diabetes Investig2010221-282310.1111/j.2040‑1124.2010.00022.x
     [Google Scholar]
  49. TV. TK. SM. JH. Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients.Diabetologia20024581111111910.1007/s00125‑002‑0878‑612189441
     [Google Scholar]
  50. GuptaV. Glucagon-like peptide-1 analogues: An overview.Indian J. Endocrinol. Metab.201317341342110.4103/2230‑8210.11162523869296
     [Google Scholar]
  51. Gomez-PeraltaF. AbreuC. Gomez-RodriguezS. BarrancoR.J. UmpierrezG.E. Safety and efficacy of DPP4 inhibitor and basal insulin in type 2 diabetes: An updated review and challenging clinical scenarios.Diabetes Ther.2018951775178910.1007/s13300‑018‑0488‑z30117055
     [Google Scholar]
  52. KanazawaI. TanakaK. NotsuM. TanakaS. KiyoharaN. KoikeS. YamaneY. TadaY. SasakiM. YamauchiM. SugimotoT. Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment.Diabetes Res. Clin. Pract.201712391710.1016/j.diabres.2016.11.01027914297
     [Google Scholar]
  53. YajimaT. YajimaK. HayashiM. TakahashiH. YasudaK. Efficacy and safety of teneligliptin in addition to insulin therapy in type 2 diabetes mellitus patients on hemodialysis evaluated by continuous glucose monitoring.Diabetes Res. Clin. Pract.2016122788310.1016/j.diabres.2016.10.01627810689
     [Google Scholar]
  54. SalvoF. MooreN. ArnaudM. Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: Systematic review and meta-analysis.BMJ2016353i223110.1136/bmj.i2231
     [Google Scholar]
  55. SharmaM.D. Potential for combination of dipeptidyl peptidase‐4 inhibitors and sodium‐glucose co‐transporter‐2 inhibitors for the treatment of type 2 diabetes.Diabetes Obes. Metab.201517761662110.1111/dom.1245125690671
     [Google Scholar]
  56. DeFronzoR. Triplitt Cersosimo Pioglitazone and alogliptin combination therapy in type 2 diabetes: A pathophysiologically sound treatment.Vasc. Health Risk Manag.2010667169010.2147/VHRM.S485220859539
     [Google Scholar]
  57. JiangM. LiuQ. JiangT. NizigiyimanaP. LeiM. Adding sodium–glucose co-transporter 2 inhibitors to sulfonylureas and risk of hypoglycemia: A systematic review and meta-analysis of randomized controlled trials.Front. Endocrinol. (Lausanne)20211271319210.3389/fendo.2021.71319234744998
     [Google Scholar]
  58. TentolourisA. VlachakisP. TzeraviniE. EleftheriadouI. TentolourisN. SGLT2 inhibitors: A review of their antidiabetic and cardioprotective effects.Int. J. Environ. Res. Public Health20191616296510.3390/ijerph1616296531426529
     [Google Scholar]
  59. LiC. LuoJ. JiangM. WangK. The efficacy and safety of the combination therapy with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes mellitus: A systematic review and meta-analysis.Front. Pharmacol.20221383827710.3389/fphar.2022.838277
     [Google Scholar]
  60. OkishioS. YamaguchiK. IshibaH. TochikiN. YanoK. TakahashiA. KataokaS. OkudaK. SekoY. LiuY. FujiiH. TakahashiD. ItoY. KamonJ. UmemuraA. MoriguchiM. YasuiK. OkanoueT. ItohY. PPARα agonist and metformin co-treatment ameliorates NASH in mice induced by a choline-deficient, amino acid-defined diet with 45% fat.Sci. Rep.20201011957810.1038/s41598‑020‑75805‑z33177546
     [Google Scholar]
  61. DasA.K. WangnooS.K. ChawlaR. ShaikhA. BantwalG. KalraP. JaggiS. AbhyankarM.V. PrasadA. SardaP. Expert consensus on triple combination of glimepiride, metformin, and voglibose usage in patients with type 2 diabetes mellitus in indian settings.J Diabetol202213214515310.4103/jod.jod_118_21
     [Google Scholar]
  62. FaruquiA.A. Safety and efficacy of fixed dose combination of voglibose, glimepiride and metformin in indian type 2 diabetes mellitus patients.Advances in Diabetes and Metabolism201643495410.13189/adm.2016.040302
     [Google Scholar]
  63. LingvayI. BeetzN. SennewaldR. Schuler-MetzA. BertulisJ. LoleyC. LangB. LippertC. LeeJ. ManningL.S. TeradaD. Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes.Postgrad. Med.2020132433734510.1080/00325481.2020.175022832366156
     [Google Scholar]
  64. JohnM. GopinathD. KalraS. Triple fixed drug combinations in type 2 diabetes.Indian J. Endocrinol. Metab.201519331131310.4103/2230‑8210.15273925932383
     [Google Scholar]
  65. DonnanP.T. MacDonaldT.M. MorrisA.D. Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: A retrospective cohort study.Diabet. Med.200219427928410.1046/j.1464‑5491.2002.00689.x11942998
     [Google Scholar]
  66. RubinaC.R. Anti-diabetic drugs and fixed dose combination therapy.Res. Rev. J. Pharm. Pharm. Sci.201434
     [Google Scholar]
  67. SunW. SandersonP.E. ZhengW. Drug combination therapy increases successful drug repositioning.Drug Discov. Today20162171189119510.1016/j.drudis.2016.05.01527240777
     [Google Scholar]
  68. KingP. PeacockI. DonnellyR. The UK Prospective Diabetes Study (UKPDS): Clinical and therapeutic implications for type 2 diabetes.Br. J. Clin. Pharmacol.199948564364810.1046/j.1365‑2125.1999.00092.x
     [Google Scholar]
  69. MatthewsD.R. Early combination therapy provides better glycaemic durability than a stepwise approach in newly diagnosed type ii diabetes.Diabetes Ther.202011112465247610.1007/s13300‑020‑00926‑732975711
     [Google Scholar]
  70. JiL. ChanJ.C.N. YuM. YoonK.H. KimS.G. ChoiS.H. HuangC.N. Te TuS. WangC.Y. PaldániusP.M. SheuW.H.H. Early combination versus initial metformin monotherapy in the management of newly diagnosed type 2 diabetes: An East Asian perspective.Diabetes Obes. Metab.202123131710.1111/dom.1420532991073
     [Google Scholar]
  71. Van GaalL.F De LeeuwI. Rationale and options for combination therapy in the treatment of type 2 diabetes.Diabetologia200346Suppl 1M44M5010.1007/s00125‑002‑0936‑0
     [Google Scholar]
  72. KrentzAJ. BaileyCJ. Oral antidiabetic agents: Current role in type 2 diabetes mellitus.Drugs201265338541110.2165/00003495‑200565030‑00005
     [Google Scholar]
  73. LunaB. FeinglosMN. Oral agents in the management of type 2 diabetes mellitus.Am Fam Physician200163917475611352285
     [Google Scholar]
  74. DiSantoR.M. SubramanianV. GuZ. Recent advances in nanotechnology for diabetes treatment.Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.20157454856410.1002/wnan.132925641955
     [Google Scholar]
  75. SinghM.N. HemantK.S. RamM. ShivakumarH.G. Microencapsulation: A promising technique for controlled drug delivery.Res. Pharm. Sci.201052657721589795
     [Google Scholar]
  76. GandhiB. Multi-particulates drug delivery systems: A review.Int J Pharm Chem Sci20132316201626
     [Google Scholar]
  77. Al-HashimiN. BeggN. AlanyR.G. HassaninH. ElshaerA. Oral modified release multiple-unit particulate systems: Compressed pellets, microparticles and nanoparticles.Pharmaceutics201810417610.3390/pharmaceutics10040176
     [Google Scholar]
  78. GuptaY. RamachandranS. Fixed dose drug combinations: Issues and challenges in India.Indian J. Pharmacol.201648434734910.4103/0253‑7613.18620027756941
     [Google Scholar]
  79. VadaliyaS. K. VadaliyaK.R. DesaiH.T. PatelJ.K. Formulation and in-vitro evaluation of floating microspheres of anti-diabetic drug prepared by solvent evaporation method.Int J Pharm Chem Sci201321397403
     [Google Scholar]
  80. MullaT.S. SalunkheV.R. BhingeS.D. MohireN. Formulation, design and optimization of antidiabetic drug loaded microspheres.Polym. Bull.20238066171619610.1007/s00289‑022‑04325‑9
     [Google Scholar]
  81. NavaneethaK. Ramakrishna ReddyV. B. ChinnalaK. M. Formulation development and in-vitro characterization of sitagliptin microspheres.J Pharm Res20165808917561767
     [Google Scholar]
  82. DP. YanmanagandlaD. SripadaR.D. Formulation and evaluation of linagliptin mucoadhesive microspheres.Int Res J Pharm201895111710.7897/2230‑8407.09567
     [Google Scholar]
  83. DewanI. IslamS. RanaS. Characterization and compatibility studies of different rate retardant polymer loaded microspheres by solvent evaporation technique: In vitro-in vivo study of vildagliptin as a model drug.J Drug Deliv2015201549680710.1155/2015/496807
     [Google Scholar]
  84. MishraA. Formulation and evaluation of floating microspheres of an anti-diabetic agent.Int J Drug Develop Res2018102711
     [Google Scholar]
  85. JainA.K. SahuP. MishraK. JainS.K. Repaglinide and metformin-loaded amberlite resin-based floating microspheres for the effective management of type 2 diabetes.Curr. Drug Deliv.202118565466810.2174/156720181766620102610561133106142
     [Google Scholar]
  86. LalJ.S. RadhaD. DevakyK.S. Drug release studies of metformin hydrochloride from chitosan - Mango leaf extract microspheres.J. Drug Deliv. Sci. Technol.20238410452410.1016/j.jddst.2023.104524
     [Google Scholar]
  87. KumariN. NanjappaiahM.H. NaikawadiA.A. KulkarniR. Composite microspheres of rosin gum and ethyl cellulose for controlled release of an anti- diabetic drug: In vitro and in- vivo assessment.Drug Deliv Lett20144322723510.2174/2210303104666140909004015
     [Google Scholar]
  88. RizgW.Y. NaveenN.R. KurakulaM. SafhiA.Y. MurshidS.S. MushtaqR.Y. AbualsununW.A. AlharbiM. BakhaidarR.B. AlmehmadyA.M. SalawiA. Al FateaseA. HosnyK.M. Augmentation of antidiabetic activity of glibenclamide microspheres using S-protected okra powered by QbD: Scintigraphy and in vivo studies.Pharmaceuticals (Basel)202215449110.3390/ph1504049135455488
     [Google Scholar]
  89. SharmaM. ChoudhuryP.K. DevS.K. JainK. Characterization and in vitro evaluation of cellulose acetate microspheres for anti-diabetic drug: Voglibose.J. Hosp. Pharm.2017
     [Google Scholar]
  90. WangYutong. Exenatide loaded PLGA microspheres for long-acting antidiabetic therapy: Preparation, characterization, pharmacokinetics and pharmacodynamics.RSC Adv201663745210.1039/C6RA02994A
     [Google Scholar]
  91. GabaP. SinghS. GabaM. GuptaG.D. Galactomannan gum coated mucoadhesive microspheres of glipizide for treatment of type 2 diabetes mellitus: In vitro and in vivo evaluation.Saudi Pharm. J.201119314315210.1016/j.jsps.2011.02.00123960752
     [Google Scholar]
  92. AllamneniY. ReddyB.V. CharyP.D. Performance evaluation of mucoadhesive potential of sodium alginate on microspheres containing an anti-diabetic drug: Glipizide.Int. J. Pharm. Sci. Drug Res.201242115122
     [Google Scholar]
  93. GarudA. GarudN. Formulation of mucoadhesive microspheres of rosiglitazone maleate and its in vitro evaluation using ionotropic gelation technique.Ars Pharm2015562101107
     [Google Scholar]
  94. VyasS.P. Lachman Liebermans, The Theory and Practice of Industrial Pharmacy.IndiaCBS Publishers & Distributors2017293373
     [Google Scholar]
  95. SolankiN. Microspheres an innovative approach in drug delivery system.MOJ Bioequiv Bioavailab201851565810.15406/mojbb.2018.05.00083
     [Google Scholar]
  96. OberoiS. KansraP. Economic menace of diabetes in India: A systematic review.Int. J. Diabetes Dev. Ctries.202040446447510.1007/s13410‑020‑00838‑z32837090
     [Google Scholar]
  97. OzougwuO. The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus.J. Physiol. Pathophysiol.201344465710.5897/JPAP2013.0001
     [Google Scholar]
  98. KarM. ChoudhuryP. PillaiS. A Handbook on Microsphere Drug Delivery System for Antidiabetic Agents.LAP Lambert Academic Publishing20151100
     [Google Scholar]
/content/journals/cis/10.2174/012210299X306155240926065025
Loading
A Review on Diabetes: Current and Future Perspectives
Curr. Indian Sci. 2, e2210299X306155 (2024); https://doi.org/10.2174/012210299X306155240926065025
/content/journals/cis/10.2174/012210299X306155240926065025
/content/journals/cis/10.2174/012210299X306155240926065025
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Anti-diabetic drugs; Combination therapy; Drug delivery; Metabolic disorder; Microspheres; Type II DM

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test